The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.
A user shared their 3-month progress using a combined finasteride and minoxidil pill for hair loss, noting early signs of regrowth. They also use biotin shampoo/conditioner, take Vyvanse and Propranolol, and bleach/dye their hair every 3 weeks.
The conversation discusses using a liposomal gel with Adenosine and caffeine for hair loss, questioning if caffeine's role as an adenosine receptor antagonist might counteract the benefits of Adenosine or worsen hair loss.
Combining Minoxidil with Finasteride or RU58841 may cause interference, irritation, or reduced absorption. It might be better to apply one topical at a time and wait an hour before applying another.
Prolonged use of topical minoxidil and finasteride can lead to neuroendocrine and autonomic dysfunction, causing severe sensitivity and side effects. Recovery involves avoiding these treatments, supporting neurosteroid recovery, calming the sympathetic system, and rebuilding scalp health naturally.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.
The conversation is about using coenzyme Q10 for hair loss alongside dutasteride. The effectiveness of coenzyme Q10 for treating androgenetic alopecia is questioned due to a lack of evidence.
Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
The conversation is about choosing a local hair transplant surgeon in Southern California, with specific mentions of Dr. Ken Williams, Dr. Varona, Dr. Sean Behnam, Dr. Amir Yazdan, and Dr. Nader. The user prefers not to consider options outside the U.S. due to safety concerns and cost issues with Dr. Mohebi.
The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.
The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.
The user felt pressured during a hair transplant consultation at Bosley, where they were advised to undergo FUT surgery and use a laser cap for maintenance, but did not meet with a doctor. Other users recommended seeking a second opinion from reputable doctors like Dr. Rassman and suggested trying finasteride first.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Sons offers free Biotin capsules, Thickening Clay, or Conditioner to UK men for hair care testing. Interested individuals can apply online to receive these products.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.
A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.
The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.
The user has been using 1mg finasteride and biotin-collagen supplements for 5 months, noticing some progress in hair regrowth. They also use various oils and shampoos, plan to start oral minoxidil, and seek advice on improving their hair care routine.
A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.